| 05/06/2026 3:06 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/05/2026 11:15 PM | Vanda Pharmaceuticals (1347178) Filer | Form EFFECT | |
| 04/24/2026 3:35 PM | Duncan Charles Cliff (2130896) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/24/2026 3:36 PM | Duncan Charles Cliff (2130896) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/23/2026 3:53 PM | Vanda Pharmaceuticals (1347178) Filer | Form ARS | |
| 04/23/2026 3:48 PM | Vanda Pharmaceuticals (1347178) Filer | Form DEF 14A | |
| 04/23/2026 3:50 PM | Vanda Pharmaceuticals (1347178) Filer | Form DEFA14A | |
| 04/22/2026 4:23 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/13/2026 4:37 PM | Howell Scott Laverne (2128384) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/13/2026 4:38 PM | Polymeropoulos Christos Vasilios Mihael (2128392) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/27/2026 12:55 PM | Vanda Pharmaceuticals (1347178) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
Get the Latest News and Ratings for VNDA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 03/10/2026 3:47 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/04/2026 5:51 PM | Birznieks Gunther (1702031) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 5:51 PM | Polymeropoulos Mihael Hristos (1355537) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 5:52 PM | Vanda Pharmaceuticals (1347178) Issuer Wijkstrom Joakim (1785888) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 5:53 PM | Moran Kevin Patrick (1806596) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 5:54 PM | Vanda Pharmaceuticals (1347178) Issuer Williams Timothy (1748392) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 8:43 PM | Vanda Pharmaceuticals (1347178) Subject Williams Timothy (1748392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/02/2026 8:27 PM | Birznieks Gunther (1702031) Reporting Vanda Pharmaceuticals (1347178) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/02/2026 8:15 PM | Polymeropoulos Mihael Hristos (1355537) Reporting Vanda Pharmaceuticals (1347178) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/02/2026 8:18 PM | Vanda Pharmaceuticals (1347178) Subject Wijkstrom Joakim (1785888) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/02/2026 8:09 PM | Moran Kevin Patrick (1806596) Reporting Vanda Pharmaceuticals (1347178) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/24/2026 3:28 PM | Honore Tage (1967946) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/23/2026 7:03 PM | Honore Tage (1967946) Reporting Vanda Pharmaceuticals (1347178) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/23/2026 6:00 AM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/19/2026 4:50 PM | Vanda Pharmaceuticals (1347178) Issuer Williams Timothy (1748392) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 4:51 PM | Birznieks Gunther (1702031) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 4:53 PM | Vanda Pharmaceuticals (1347178) Issuer Wijkstrom Joakim (1785888) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 4:46 PM | Polymeropoulos Mihael Hristos (1355537) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 4:48 PM | Moran Kevin Patrick (1806596) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/19/2026 3:31 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/12/2026 6:17 AM | Vanda Pharmaceuticals (1347178) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 02/12/2026 6:04 AM | Vanda Pharmaceuticals (1347178) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 01/21/2026 11:26 AM | BlackRock Portfolio Management LLC (2052113) Filed by Vanda Pharmaceuticals (1347178) Subject | Form SCHEDULE 13G/A | |
| 01/09/2026 3:23 PM | MILLENNIUM MANAGEMENT LLC (1273087) Filed by Vanda Pharmaceuticals (1347178) Subject | Form SCHEDULE 13G/A | |
| 01/08/2026 6:09 AM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/30/2025 5:45 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/04/2025 3:39 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/28/2025 6:06 AM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/30/2025 6:23 AM | Vanda Pharmaceuticals (1347178) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/29/2025 3:08 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
|
| 10/01/2025 4:10 PM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2025 7:57 AM | Vanda Pharmaceuticals (1347178) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2025 6:34 AM | Vanda Pharmaceuticals (1347178) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/01/2025 3:31 PM | MILLENNIUM MANAGEMENT LLC (1273087) Filed by Vanda Pharmaceuticals (1347178) Subject | Form SCHEDULE 13G | |
| 06/16/2025 8:10 PM | Mitchell Stephen Ray (1802653) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/13/2025 8:40 PM | Mitchell Stephen Ray (1802653) Reporting Vanda Pharmaceuticals (1347178) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/09/2025 4:35 PM | DUGAN RICHARD W (1263499) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 4:35 PM | Chrousos Phaedra (1774518) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 4:36 PM | Mitchell Stephen Ray (1802653) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 4:34 PM | Vanda Pharmaceuticals (1347178) Issuer Ward Anne Sempowski (1790117) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 4:34 PM | Honore Tage (1967946) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/27/2025 6:01 AM | Vanda Pharmaceuticals (1347178) Filer | Form DEFA14A | |
| 05/21/2025 8:23 PM | Polymeropoulos Mihael Hristos (1355537) Reporting Vanda Pharmaceuticals (1347178) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/08/2025 6:06 AM | Vanda Pharmaceuticals (1347178) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |